DOI: https://doi.org/10.22141/2224-1507.3.11.2013.82340

Changes in the Structural and Functional State of Bone Tissue, the Level of Osteoprotegerin in Women with Ischemic Heart Disease in Postmenopause

O.I. Nishkumay

Abstract


Epidemiological evidence of the correlation in development of osteoporosis and cardiovascular diseases in menopause are actively discussed. The objective of the study was to determine the changes in the structural and functional state of the skeletal system, the level of osteoprotegerin in women with ischemic heart disease in postmenopause.
The study involved 148 postmenopausal women, they were divided into groups depending on the presence of ischemic heart disease and osteoporosis (mean age 63.5 ± 5.9 years, duration of postmenopause on average — 6.10 ± 0.65 years). Everyone underwent densitometric examination, identification of markers of resorption and bone formation, osteoprotegerin. The results showed that in postmenopausal women with ischemic heart disease in the presence of osteoporosis more significant decrease in T-scores, levels of osteocalcin and osteoprotegerin was defined.


Keywords


menopause; osteoporosis; ischemic heart disease; osteoprotegerin

References


Амосова Е.Н. Диагностика и лечение стабильной стенокардии. Основные положения рекомендаций Европейского кардиологического общества, 2006. Ч. ІІ / Е.Н. Амосова, Л.А. Ткаченко // Серце і судини. — 2007. — № 2. — С. 17-38.

Дзяк Г.В. Причины и факторы первичной инвалидизации лиц, перенесших острый инфаркт миокарда / Г.В. Дзяк, Е.В. Охромий // Запорож. мед. журн. — 2007. — № 5. — С. 46-49.

Поворознюк В.В. Заболевания костно-мышечной системы и возраст / В.В. Поворознюк // Consilium medicum. — 2010. — № 1(23). — С. 18-22.

Рекомендації з діагностики, профілактики та лікування системного остеопорозу у жінок в постменопаузальному періоді: метод. рекомендації / В.М. Коваленко, В.В. Поворознюк [та ін.]. — Український центр наукової інформації і патентно-ліцензійної роботи, 2010. — 50 с.

Чуклин С.Н. Интерлейкины / С.Н. Чуклин, А.А. Переяслов. — Львов: Лига-Пресс, 2005. — 481 с.

Aortic calcification and the risk of osteoporosis and fractures / E. Schoulz, K. Afrai // J. of Clinical Endocrinology & Metabolism. — 2010. — Vol. 89(9). — P. 4246-4253.

Hamerman D. Osteoporosis and atherosclerosis: biological linkages and the emergence of dual-purpose therapies / D. Hamerman // QJM. — 2005. — Vol. 98, № 7. — P. 467-484.

Ivanisevic М. Effects of therapy on estro-progestagene on lipid profile and hormone status of women with premature ovarian failure // М. Ivanisevic, S. Vujovic, D. Sljivancanin // Maturitas. — 2009. — Vol. 63, Suppl. 1. — P. S58.

Kanis J.A. Developmentanduseof FRAX / J.A. Kanis // Osteoporos Int. — 2008. — Vol. 19. — P. 1395-1408.

Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification / N. Bucay, I. Sarosi, C.R. Dunstan [et al.] // Genes. Dev. — 1998. — Vol. 12. — P. 1260-1268.

Schoppet M. Increased Osteoprotegerin serum levels in men with coronary artery disease / M. Schoppet, A. Sattler // J. of Clinical Endocrinology & Metabolism. — 2003. — Vol. 88, № 3. — P. 1024-1028.

Tremollieres F. BMD inpredictionofotherconditions / F. Tremollieres, C. Ribot // Maturitas. — 2010. — Vol. 63, Suppl. 1. — P. S13.

Vega D. Clinical review the role of receptor activation of nuclear factor-kappa B (RANK)/RANK ligand/osteoprotegerin: clinical implications / D. Vega, N.M. Maalouf, K. Sakhaee // J. Clin. Endocrinol. — 2007. — Vol. 92(12). — Р. 4514-4521.




Copyright (c) 2016 PAIN. JOINTS. SPINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© Publishing House Zaslavsky, 1997-2018

 

   Seo анализ сайта